18:49 , Jun 27, 2019 |  BC Innovations  |  Distillery Therapeutics

Ketorolac and resolvins to prevent cancer recurrence

DISEASE CATEGORY: Cancer INDICATION: Cancer, lung cancer, lymphoma, melanoma, colorectal cancer The generic COX inhibitor ketorolac and/or the resolvins RvD2, RvD3 and RvD4 could help prevent cancer recurrence due to chemotherapy- or surgery-induced inflammation. In...
22:04 , Dec 31, 2018 |  BC Extra  |  Company News

Heron's non-opioid HTX-011 gets Priority Review

FDA accepted and granted Priority Review to an NDA for HTX-011 from Heron Therapeutics Inc. (NASDAQ:HRTX) for postoperative pain management. The PDUFA date is April 30. Heron said FDA indicated that it has no plans...
18:27 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Heron's pain candidate meets in Phase IIb ahead of NDA

Heron Therapeutics Inc. (NASDAQ:HRTX) reported that HTX-011 met the primary endpoint in a pair of Phase IIb trials to treat postoperative pain. Heron intends to submit an NDA to FDA next half for the candidate....
18:57 , Jun 21, 2018 |  BC Extra  |  Clinical News

Heron flying on Phase IIb pain data ahead of NDA

Heron Therapeutics Inc. (NASDAQ:HRTX) added $9.25 (30%) to $39.95 on Thursday after reporting that HTX-011 met the primary endpoint in a pair of Phase IIb trials to treat postoperative pain. The stock move added more...
15:17 , Mar 30, 2018 |  BC Week In Review  |  Financial News

Pain company Heron raises $156M follow-on

Pain company Heron Therapeutics Inc. (NASDAQ:HRTX) raised $156 million on March 29 via the sale of 6 million shares at $26 in a follow-on underwritten by Jefferies, Cowen, Evercore ISI, Cantor, JMP Securities, LifeSci Capital,...
16:29 , Mar 29, 2018 |  BC Extra  |  Financial News

Pain company Heron raises $156M

Heron Therapeutics Inc. (NASDAQ:HRTX) raised $156 million via the sale of 6 million shares at $26 in a follow-on underwritten by Jefferies, Cowen, Evercore ISI, Cantor, JMP Securities, LifeSci Capital, Lake Street Capital Markets, National...
17:02 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Heron’s HTX-011 meets Phase III postoperative pain endpoints

Heron Therapeutics Inc. (NASDAQ:HRTX) said HTX-011 met the primary and key secondary endpoints in the Phase III EPOCH1 and EPOCH2 trials to treat postoperative pain. The company reiterated its plan to submit an NDA to...
20:27 , Mar 19, 2018 |  BC Extra  |  Clinical News

Heron’s HTX-011 meets postoperative pain endpoints

Heron Therapeutics Inc. (NASDAQ:HRTX) gained $5.80 (27%) to $27.30 on Monday after it said HTX-011 met the primary and key secondary endpoints in the Phase III EPOCH1 and EPOCH2 trials to treat postoperative pain. The...
19:10 , Mar 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Shock / trauma Rat studies suggest the generic ADRA2 agonist/COX inhibitor guanabenz could help treat traumatic brain injury (TBI). In a rat model of TBI, intraperitoneal (i.p.) injection of guanabenz 30 minutes post-injury increased...
23:42 , Nov 30, 2017 |  BC Week In Review  |  Company News

Omeros, Par settle Omidria patent infringement lawsuit

In October, Omeros Corp. (NASDAQ:OMER) said it and Par Pharmaceuticals Inc. settled a patent infringement lawsuit concerning Par's proposed generic version of Omeros' Omidria ketorolac/phenylephrine. Par, which Endo International plc (NASDAQ:ENDP) acquired in 2015, had...